Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib

Background: The addition of neutrophil-to-lymphocyte ratio (NLR) and bone metastases to the International Metastatic RCC Database Consortium (IMDC) score (by the Meet-URO score) has been shown to better stratify pretreated metastatic renal cell carcinoma (mRCC) patients receiving nivolumab. This stu...

Full description

Bibliographic Details
Main Authors: Sara Elena Rebuzzi, Luigi Cerbone, Alessio Signori, Matteo Santoni, Veronica Murianni, Ugo De Giorgi, Giuseppe Procopio, Camillo Porta, Michele Milella, Umberto Basso, Francesco Massari, Marco Maruzzo, Roberto Iacovelli, Nicola Battelli, Luca Carmisciano, Giuseppe Luigi Banna, Sebastiano Buti, Giuseppe Fornarini
Format: Article
Language:English
Published: SAGE Publishing 2022-02-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359221079580

Internet

https://doi.org/10.1177/17588359221079580

Similar Items